Compare · KRBP vs VGR
KRBP vs VGR
Side-by-side comparison of Kiromic BioPharma Inc. (KRBP) and Vector Group Ltd. (VGR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KRBP and VGR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- VGR is the larger of the two at $1.74B, about 114.7x KRBP ($15.1M).
- VGR has more recent analyst coverage (4 ratings vs 0 for KRBP).
- Company
- Kiromic BioPharma Inc.
- Vector Group Ltd.
- Price
- $1.48-1.33%
- $14.99+0.20%
- Market cap
- $15.1M
- $1.74B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 4
Kiromic BioPharma Inc.
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Vector Group Ltd.
Vector Group Ltd., through its subsidiaries, manufactures and sells cigarettes in the United States. It operates in two segments, Tobacco and Real Estate. The company produces cigarettes in 100 combinations under the EAGLE 20's, Pyramid, Montego, Grand Prix, Liggett Select, Eve, and USA brand names, as well as various partner and private label brands. In addition, it provides residential real estate brokerage, relocation, real estate sales and marketing, and title insurance services to real estate buyers and financial institutions; manages cooperative apartment buildings, condominium apartment buildings, and rental apartment buildings; and invests in, acquires, and owns real estate properties or projects, as well as develops land. Further, the company operates elliman.com, a website that enables consumers to search properties and access current market information, as well as offers building and neighborhood guides, and other interactive content. It markets and sells its cigarettes to wholesalers and distributors of tobacco and convenience products, as well as grocery, drug, and convenience store chains. The company was formerly known as Brooke Group Ltd. and changed its name to Vector Group Ltd. in May 2000. Vector Group Ltd. was founded in 1873 and is based in Miami, Florida.
Latest KRBP
- Kiromic BioPharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
- Kiromic BioPharma Inc. filed SEC Form 8-K: Other Events
- Amendment: SEC Form S-1/A filed by Kiromic BioPharma Inc.
- Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
- SEC Form 10-K filed by Kiromic BioPharma Inc.
- Amendment: Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
- SEC Form S-1 filed by Kiromic BioPharma Inc.
- Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
Latest VGR
- SEC Form 15-12G filed by Vector Group Ltd.
- Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.
- SEC Form EFFECT filed by Vector Group Ltd.